BACKGROUND: Squamous cell cancers of the anal canal (ASCC) are increasing in frequency and lack effective therapies for advanced disease. Although an association with human papillomavirus (HPV) has been established, little is known about the molecular characterization of ASCC. A comprehensive genomic analysis of ASCC was undertaken to identify novel genomic alterations (GAs) that will inform therapeutic choices for patients with advanced disease. PATIENTS AND METHODS: Hybrid-capture-based next-generation sequencing of exons from 236 cancer-related genes and intronic regions from 19 genes commonly rearranged in cancer was performed on 70 patients with ASCC. HPV status was assessed by aligning tumor sequencing reads to HPV viral genomes. GAs were identified using an established algorithm and correlated with HPV status. RESULTS: Sixty-one samples (87%) were HPV-positive. A mean of 3.5 GAs per sample was identified. Recurrent alterations in phosphoinositol-3-kinase pathway (PI3K/AKT/mTOR) genes including amplifications and homozygous deletions were present in 63% of cases. Clinically relevant GAs in genes involved in DNA repair, chromatin remodeling, or receptor tyrosine kinase signaling were observed in 30% of cases. Loss-of-function mutations in TP53 and CDKN2A were significantly enhanced in HPV-negative cases (P < 0.0001). CONCLUSIONS: This is the first comprehensive genomic analysis of ASCC, and the results suggest new therapeutic approaches. Differing genomic profiles between HPV-associated and HPV-negative ASCC warrants further investigation and may require novel therapeutic and preventive strategies.
BACKGROUND:Squamous cell cancers of the anal canal (ASCC) are increasing in frequency and lack effective therapies for advanced disease. Although an association with human papillomavirus (HPV) has been established, little is known about the molecular characterization of ASCC. A comprehensive genomic analysis of ASCC was undertaken to identify novel genomic alterations (GAs) that will inform therapeutic choices for patients with advanced disease. PATIENTS AND METHODS: Hybrid-capture-based next-generation sequencing of exons from 236 cancer-related genes and intronic regions from 19 genes commonly rearranged in cancer was performed on 70 patients with ASCC. HPV status was assessed by aligning tumor sequencing reads to HPV viral genomes. GAs were identified using an established algorithm and correlated with HPV status. RESULTS: Sixty-one samples (87%) were HPV-positive. A mean of 3.5 GAs per sample was identified. Recurrent alterations in phosphoinositol-3-kinase pathway (PI3K/AKT/mTOR) genes including amplifications and homozygous deletions were present in 63% of cases. Clinically relevant GAs in genes involved in DNA repair, chromatin remodeling, or receptor tyrosine kinase signaling were observed in 30% of cases. Loss-of-function mutations in TP53 and CDKN2A were significantly enhanced in HPV-negative cases (P < 0.0001). CONCLUSIONS: This is the first comprehensive genomic analysis of ASCC, and the results suggest new therapeutic approaches. Differing genomic profiles between HPV-associated and HPV-negative ASCC warrants further investigation and may require novel therapeutic and preventive strategies.
Authors: Kent W Mouw; James M Cleary; Brendan Reardon; Jonathan Pike; Lior Z Braunstein; Jaegil Kim; Ali Amin-Mansour; Diana Miao; Alexis Damish; Joanna Chin; Patrick A Ott; Charles S Fuchs; Neil E Martin; Gad Getz; Scott Carter; Harvey J Mamon; Jason L Hornick; Eliezer M Van Allen; Alan D D'Andrea Journal: Clin Cancer Res Date: 2016-11-16 Impact factor: 12.531
Authors: Sebastian Mondaca; Walid K Chatila; David Bates; Jaclyn F Hechtman; Andrea Cercek; Neil H Segal; Zsofia K Stadler; Anna M Varghese; Ritika Kundra; Marinela Capanu; Jinru Shia; Nikolaus Schultz; Leonard Saltz; Rona Yaeger Journal: Clin Colorectal Cancer Date: 2018-09-21 Impact factor: 4.481
Authors: Mohamed E Salem; Alberto Puccini; Axel Grothey; Derek Raghavan; Richard M Goldberg; Joanne Xiu; W Michael Korn; Benjamin A Weinberg; Jimmy J Hwang; Anthony F Shields; John L Marshall; Philip A Philip; Heinz-Josef Lenz Journal: Mol Cancer Res Date: 2018-03-09 Impact factor: 5.852
Authors: Van K Morris; Mohamed E Salem; Halla Nimeiri; Syma Iqbal; Preet Singh; Kristen Ciombor; Blase Polite; Dustin Deming; Emily Chan; James L Wade; Lianchun Xiao; Tanios Bekaii-Saab; Luis Vence; Jorge Blando; Armeen Mahvash; Wai Chin Foo; Chimela Ohaji; Manolo Pasia; Gail Bland; Aki Ohinata; Jane Rogers; Amir Mehdizadeh; Kimberly Banks; Richard Lanman; Robert A Wolff; Howard Streicher; James Allison; Padmanee Sharma; Cathy Eng Journal: Lancet Oncol Date: 2017-02-18 Impact factor: 41.316
Authors: Corinne M Doll; Jennifer Moughan; Alexander Klimowicz; Clement K Ho; Elizabeth N Kornaga; Susan P Lees-Miller; Jaffer A Ajani; Christopher H Crane; Lisa A Kachnic; Gordon S Okawara; Lawrence B Berk; Kevin S Roof; Mark J Becker; David L Grisell; Robert J Ellis; Paul W Sperduto; Gerald W Marsa; Chandan Guha; Anthony M Magliocco Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-23 Impact factor: 7.038
Authors: David S Hong; Kathleen Moore; Manish Patel; Stefan C Grant; Howard A Burris; William N William; Suzanne Jones; Funda Meric-Bernstam; Jeffrey Infante; Lisa Golden; Wei Zhang; Ricardo Martinez; Sameera Wijayawardana; Richard Beckmann; Aimee Bence Lin; Cathy Eng; Johanna Bendell Journal: Clin Cancer Res Date: 2018-04-11 Impact factor: 12.531